Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) traded up 12.9% during trading on Tuesday . The stock traded as high as C$2.72 and last traded at C$2.72. 93,798 shares were traded during mid-day trading, a decline of 29% from the average session volume of 132,492 shares. The stock had previously closed at C$2.41.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating on shares of Cardiol Therapeutics in a report on Monday, April 22nd.
Check Out Our Latest Research Report on Cardiol Therapeutics
Cardiol Therapeutics Stock Up 15.4 %
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.
See Also
- Five stocks we like better than Cardiol Therapeutics
- What is the S&P/TSX Index?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What is a Secondary Public Offering? What Investors Need to Know
- Hilton Demonstrates Asset Light is Right for Investors
- What is the Shanghai Stock Exchange Composite Index?
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.